Concepedia

Adil Daud

AD

Statistics

Publications

214

Citations

46K

H-Index

85

Active since

1988

Affiliations

University of California, San Francisco(Current)

Moffitt Cancer Center

Angeles Clinic and Research Institute

Merck & Co., Inc., Rahway, NJ, USA (United States)

University of California, Los Angeles

Adil Daud is an author at University of California, San Francisco specializing in oncology, medicine, and cancer immunotherapy.

Publications per year

1988–2025

214

Publications

214

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid, Caroline Robert, Adil Daud et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

Medicine, Immunology, Oncology +17

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty, J. Infante, Adil Daud et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +16

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Caroline Robert, Antoni Ribas, Jedd D. Wolchok et al. · The Lancet · 2014 · 1.8K citations

Pharmacy, Oncology, Pharmacotherapy +17

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas, Igor Puzanov, Reinhard Dummer et al. · The Lancet Oncology · 2015 · 1.6K citations · Full text

Medicine, Clinical Sciences, Oncology +15

1–5 of 214